0.581
0.00 (-0.73%)
| Previous Close | 0.585 |
| Volume | 155,627 |
| Price / Earnings (Forward) | 0.320 |
| Price / Sales | 1.81 |
| Price / Book | 0.240 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -5.76 |
| Total Debt/Equity (MRQ) | 1.47% |
| Current Ratio (MRQ) | 0.370 |
| Operating Cash Flow (TTM) | -23.55 M |
| Levered Free Cash Flow (TTM) | 15.85 M |
| Return on Assets (TTM) | -25.32% |
| Return on Equity (TTM) | -60.53% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Citius Pharmaceuticals, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.5 |
| Average | -1.71 |
|
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.41% |
| % Held by Institutions | 5.69% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Miller Financial Services Llc | 30 Jun 2026 | 130,000 |
| Asset Advisory Group, Inc. | 30 Jun 2026 | 59,011 |
| Bostonpremier Wealth Llc | 30 Jun 2026 | 28,000 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |